Loading
A phase 2/3 trial testing IAH0968 in gastric & gastro-oesophageal junction cancer, now recruiting.
To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer is a phase 2/3 interventional study registered as NCT06504732, led by SUNHO（China）BioPharmaceutical CO., and recruiting on the registry. Official title: A Phase II/III Clinical Study Evaluating IAH0968 in Combination or Not in Combination With the CAPEOX Regimen in HER2-expressing Advanced/Metastatic Solid Tumours and Gastric Cancer. Planned enrolment is 574 participants (estimated). The study started in 2024-08-15 and primary completion is expected in 2028-07. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares HER2-positive gastric cancer, Gastric & gastro-oesophageal junction cancer.
Shares HER2-positive gastric cancer, Gastric & gastro-oesophageal junction cancer.
Shares HER2-positive gastric cancer, Gastric & gastro-oesophageal junction cancer.
Shares HER2-positive gastric cancer, Gastric & gastro-oesophageal junction cancer.
Shares HER2-positive gastric cancer, Gastric & gastro-oesophageal junction cancer.
Shares HER2-positive gastric cancer, Gastric & gastro-oesophageal junction cancer.
Shares HER2-positive gastric cancer, Gastric & gastro-oesophageal junction cancer.
Shares HER2-positive gastric cancer, Gastric & gastro-oesophageal junction cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/